How to Trip Rapid Review
Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)
Step 2: press
Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.
- 734 results
- Evidence type
- Clinical Area
Use check boxes to select individual results below
SmartSearch available
Trip's SmartSearch engine has discovered connected searches & results. Click to show281. The Effect of Weight Loss on Anti-Müllerian Hormone Levels in Women With Polycystic Ovary Syndrome (PCOS)
(AMH) levels in obese women with polycystic ovary syndrome (PCOS) and in obese controls. The other aim of the investigators study, was to examine the effect of hypocaloric diet,physical exercise plus sibutramine on serum AMH levels, body composition, hormonal and metabolic parameters in overweight and obese patients with polycystic ovary syndrome (PCOS). Condition or disease Intervention/treatment Phase Obesity Polycystic Ovaries Syndrome Drug: Orlistat Drug: Sibutramine Behavioral: Diet (...) and physical exercise Phase 4 Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Estimated Enrollment : 200 participants Allocation: Non-Randomized Intervention Model: Parallel Assignment Masking: None (Open Label) Primary Purpose: Treatment Official Title: The Effect of Weight Loss With Orlistat or Sibutramine Administration , Hypocaloric Diet and Physical Exercise , on AMH Levels, in Women With Polycystic Ovary Syndrome Study Start Date : January 2004
2011 Clinical Trials
282. Dextromethorphan for Diabetic Macular Edema
mesylates; ergotamine; escitalopram; fluoxetine; fluvoxamine; frovatriptan; imipramine; isocarboxazid; linezolid; lithium; maprotiline; meperidine; methylergonovine; milnacipran; mirtazapine; moclobemide; naratriptan; nefazodone; nortriptyline; paroxetine; phenelzine; procarbazine; promethazine; protriptyline; rasagiline; rizatriptan; SAMe (S-adenosylmethionine); selegiline; sertraline; sibutramine; St. Johns wort; sumatriptan; tapentadol; tramadol; tranylcypromine; trazodone; trimipramine; tryptophan
2011 Clinical Trials
283. Ideas Moving Parents and Adolescents to Change Together (IMPACT)
), Ziprasidone (Geodon), Carbamazepine (Tegretol), Valproic acid (Depakote/Depakene/Depacon), Aripiprazole (Abilify), Orlistat (Xenical), Sibutramine (Meridia), Phentermine, Diethylproprion (Tenuate), Topirimate (Topamax), glitazones (thiazolidinediones) Inability to understand English Stage 2 hypertension or stage 1 hypertension with end organ damage (left ventricular hypertrophy, microalbuminuria) Severe behavioral problems that preclude group participation (as reported by parent/guardian) Child
2011 Clinical Trials
284. Comparative Efficiency and Safety of Pharmacological Approaches to the Management of Obesity (Full text)
7805975 0149-5992 0 Anti-Obesity Agents 0 Bridged Bicyclo Compounds, Heterocyclic 0 Cyclobutanes 0 Lactones 95M8R751W8 Orlistat BLH9UKX9V1 Tesofensine WV5EC51866 sibutramine IM Anti-Obesity Agents therapeutic use Bridged Bicyclo Compounds, Heterocyclic therapeutic use Cyclobutanes therapeutic use Humans Lactones therapeutic use Obesity drug therapy Orlistat 2011 4 29 6 0 2011 5 6 6 0 2011 7 2 6 0 ppublish 21525481 34/Supplement_2/S349 10.2337/dc11-s255 PMC3632205 Obesity (Silver Spring). 2009 Jan;17(1
2011 Diabetes Care PubMed abstract
285. Obesity in adults (Full text)
bypass, gastric banding, mazindol, orlistat (alone and in combination with sibutramine), phentermine, sibutramine (alone and in combination with orlistat), sleeve gastrectomy, and vertical banded gastroplasty.
2011 BMJ Clinical Evidence PubMed abstract
286. Hepatic PTP1B expression involvement in the effects of Chinese medicine formula xiao-gao-jiang-zhuo using an obese rat model. (Abstract)
, the high-dose XGJZ group, the middle-dose XGJZ group, the low-dose XGJZ group, and the sibutramine group. After 14 weeks of treatment, body weight, abdominal fat, blood lipid and serum insulin level were measured, and the protein and gene expression of PTP1B in liver tissue was tested. Our data showed that the body weight of the high-dose and middle-dose groups and the sibutramine group had significant differences in comparison with the model group (p < 0.05), and all three dose groups had (...) significantly reduced abdominal fat (p < 0.05). The triglyceride level of the three dose groups and the sibutramine group, and the total cholesterol level of the middle-dose group were all significantly reduced (p < 0.05). The serum insulin of the high-dose and middle-dose groups also decreased significantly (p < 0.05). The expression of hepatic PTP1B mRNA of the three dose groups decreased significantly in comparison with the model group (p < 0.05 or 0.01). The expression of hepatic PTP1B protein
2011 American Journal of Chinese Medicine
287. Asthma Phenotypes in the Inner City
, nelfinavir); Calcium channel blockers (verapamil, diltiazem); Modafinil; Tamoxifen; non-nucleoside reverse transcriptase inhibitors; Macrolide antibiotics* (erythromycin, clarithromycin, dirithromycin, troleandomycin); chloramphenicol; nefazodone; aprepitant; St John's Wort; Rifampin*; Azole Antifungals* (ketoconazole, fluconazole, itraconazole); Sibutramine* ; bergamottin (constituent of grapefruit juice) (*may be rescreened if this therapy is short-lived); Should not be included in the study for any
2011 Clinical Trials
288. Tomato Consumption and High Density Lipoprotein-cholesterol
, estrogens or progesterone), metformin, other oral hypoglycemic agents, insulin, sibutramine, or orlistat treatment and those with daily consumption of any non-steroidal anti-inflammatory drug were also excluded. Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor. Please refer to this study by its ClinicalTrials.gov identifier (NCT
2011 Clinical Trials
289. Effects of Novel Fiber on Glucose Metabolism and Insulin Sensitivity
of medications or herbal remedies for weight loss (e.g., sibutramine, orlistat, amphetamines, phentermine, and ma huang) or use of these substances within the past 3 months Current or recent history (past 12 months) of drug, alcohol or chemical abuse. Alcohol abuse will be defined as >14 drinks per week (1 drink = 12 oz beer, 5 oz wine, or 1.5 oz hard liquor) Pregnant, breast-feeding or female of child-bearing potential who is unwilling to commit to the use of a medically approved form of contraception
2011 Clinical Trials
290. Safety and Efficacy of Exenatide Injection in Subjects With Type 2 Diabetes Mellitus
to participate and give written informed consent. Exclusion Criteria: Previous exposure to exenatide (anti-exenatide antibodies at screening) or a GLP-1 analogue. Used drugs for weight loss (for example, orlistat, sibutramine, phenylpropanolamine, rimonabant, or similar over-the-counter medications) within 3 months of screening. Received treatment within the last 30 days with a drug that has not received regulatory approval for any indication at the time of trial entry. Severe renal impairment (creatinine
2011 Clinical Trials
291. Effects of Anticholinergic or Long-Acting Beta 2 Agonist on FeNO and Pulmonary Function in SCI
; Phenylephrine; Pirbuterol; Propylhexedrine; Pseudoephedrine; Sibutramine; Terbutaline; Theophylline; Xylometazoline. Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor. Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01355991 Locations Layout table for location information United States, New Jersey Kessler
2011 Clinical Trials
292. Calcium Supplementation for a Healthy Weight (CaSHeW)
within the last six months of medications that can result in significant weight gain or weight loss, including antipsychotics, selective serotonin reuptake inhibitors, anti-epileptic drugs, appetite-suppressants such as phentermine and sibutramine, and the lipase-inhibitor orlistat. Active eating disorder History of alcoholism or substance abuse within 5 years prior to study entry. Use of a dietary supplement or medication that decreases calcium absorption History of kidney stone, hyperparathyroidism
2011 Clinical Trials
293. Changes of body weight and inflammatory markers after 12-week intervention trial: results of a double-blind, placebo-control pilot study. (Full text)
Changes of body weight and inflammatory markers after 12-week intervention trial: results of a double-blind, placebo-control pilot study. Low grade inflammation is a well-known characteristic in obese subjects. We investigated body weight changes and inflammatory markers after 12-week intervention trial.Twenty-six obese subjects were enrolled and 19 (13 men and 6 women) completed the study. Sibutramine is an FDA-approved drug for body weight control; therefore, we chose this drug
2011 Yonsei medical journal Controlled trial quality: uncertain PubMed abstract
294. Second-line therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a systematic review and mixed-treatment comparison meta-analysis. (Full text)
, meglitinides, thiazolidinediones (TZDs), dipeptidyl peptidase-4 (DPP-4) inhibitors, glucagon-like peptide-1 (GLP-1) analogues, insulins, alpha-glucosidase inhibitors, sibutramine and orlistat. All classes of second-line antihyperglycemic therapies achieved clinically meaningful reductions in hemoglobin A1c (0.6% to 1.0%). No significant differences were found between classes. Insulins and insulin secretagogues were associated with significantly more events of overall hypoglycemia than the other agents
2011 Open medicine : a peer-reviewed, independent, open-access journal PubMed abstract
295. Metformin for weight reduction in non-diabetic patients on antipsychotic drugs: a systematic review and meta-analysis. (Abstract)
reduced weight by 7.5% (95% CI 2.9 to 12.0). The effect was larger in Asians (7.8%, 95% CI 4.4 to 11.2) than in Hispanics (2.0%, 95% CI 0.7 to 3.3). In conclusion, metformin has a pronounced weight-reducing effect in antipsychotic-treated patients, especially in those with a manifest weight gain. Although direct comparisons are lacking, the observed effect on body weight compares favourably with the effect of sibutramine and orlistat, approved for weight reduction. However, metformin is not approved
2011 Journal of psychopharmacology (Oxford, England)
296. Serotonin syndrome (Full text)
effects, and is therefore not a dual action drug. Bupropion has also been suggested to cause serotonin syndrome, although as there is no evidence that it has any significant serotonergic activity, it is thought unlikely to produce the syndrome. In 2006 the United States issued an alert suggesting that the combined use of SSRIs or SNRIs and triptan medications or sibutramine could potentially lead to severe cases of serotonin syndrome. This has been disputed by other researchers as none of the cases
2012 Wikipedia PubMed abstract
297. Management of obesity (Full text)
, average weight loss on orlistat is 2.9 kg (6.4 lb), sibutramine is 4.2 kg (9.3 lb) and rimonabant is 4.7 kg (10 lb). Orlistat and rimonabant lead to a reduced incidence of diabetes, and all three drugs have some effect on . However, there is little information on how these drugs affect the longer-term complications or outcomes of obesity. In 2010 it was found that sibutramine increases the risk of and in people with a history of cardiovascular disease. There are a number of less commonly used (...) is not effective for inducing weight loss in the majority of people with obesity. It is being investigated to determine whether or not it helps with weight loss maintenance. The usefulness of certain drugs depends upon the comorbidities present. is preferred in overweight diabetics, as it may lead to mild weight loss in comparison to or . The , on the other hand, may cause weight gain, but decrease central obesity. Diabetics also achieve modest weight loss with , orlistat and sibutramine over 12–57 weeks
2012 Wikipedia PubMed abstract
298. What are the current evidence based guidelines for GP's to prescribe orlistat? What are the current NICE guidelines for initiation and continuing to prescribe? How efficient is it? "
pressure) are present. Prescribing should be started and monitored only in specialist paediatric settings7. In children aged 12 years and older, treatment with orlistat or sibutramine is recommended only if physical comorbidities (such as orthopaedic problems or sleep apnoea) or severe psychological comorbidities are present. Treatment should be started in a specialist paediatric setting, by multidisciplinary teams with experience of prescribing in this age group. Orlistat or sibutramine should (...) be prescribed for obesity in children only by a multidisciplinary team with expertise in: • drug monitoring • psychological support • behavioural interventions • interventions to increase physical activity • interventions to improve diet. Orlistat and sibutramine should be prescribed for young people only if the prescriber is willing to submit data to the proposed national registry on the use of these drugs in young people (see section 4.5.3). After drug treatment has been started in specialist care, it may
2009 TRIP Answers
299. Planned CORR: Planned Care for Obesity and Risk Reduction
psychiatric disorder that would impair compliance with the study protocol (e.g. unstable depression, bipolar, schizophrenia). Is not pregnant or does not intend to become pregnant during the 2-year study period. Is not currently taking weight-altering medications (e.g. Sibutramine (Meridia), Orlistat (Xenical, Alli)), and has not taken them in at least 3 months. Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact
2010 Clinical Trials
300. Cholesterol Absorption Inhibition Study
antidepressants, narcotic analgesics, adrenergic agents, calcium channel blockers) Concomitant medication that can alter intestinal transit (e.g. loperamide, chemical/ osmotic/bulk laxatives), or influence satiety/energy intake (e.g. sibutramine, gluco¬corticoids, anabolic steroids) Intolerance or allergy for test product. Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact
2010 Clinical Trials
To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>